1. |
World Health Organization. New report calls for urgent action to avert antimicrobial resistance crisis. (2019-04-29)[2023-04-01]. https://www.who.int/news-room/detail/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis.
|
2. |
胡付品, 郭燕, 朱德妹, 等. 2021年CHINET中国细菌耐药监测. 中国感染与化疗杂志, 2022, 22(5): 521-530.
|
3. |
Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis, 2017, 215(suppl_1): S28-S36.
|
4. |
Li Y, Li J, Hu T, et al. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China. Antimicrob Resist Infect Control, 2020, 9(1): 79.
|
5. |
Zhen X, Stalsby Lundborg C, Sun X, et al. Clinical and economic burden of carbapenem-resistant infection or colonization caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: a multicenter study in China. Antibiotics (Basel), 2020, 9(8): 514.
|
6. |
Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob, 2017, 16(1): 18.
|
7. |
Clinical and Laboratory Standards Institute. M100-S25. performance standards for antimicrobial susceptibility testing; twenty-ffifth informational supplements. Wayne PA: CLSI, 2015.
|
8. |
Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother, 2014, 58(4): 2322-2328.
|
9. |
Gutierrez-Gutierrez B, Salamanca E, De Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis, 2017, 17(7): 726-734.
|
10. |
Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother, 2017, 61(8): e00883-17.
|
11. |
Folgori L, Bielicki J. Future challenges in pediatric and neonatal sepsis: emerging pathogens and antimicrobial resistance. J Pediatr Intensive Care, 2019, 8(1): 17-24.
|
12. |
Yang D, Xie Z, Xin X, et al. A model for predicting nosocomial carbapenem-resistant Klebsiella pneumoniae infection. Biomed Rep, 2016, 5(4): 501-505.
|
13. |
Pilote L, Dasgupta K, Guru V, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ, 2007, 176(6): S1-S44.
|
14. |
Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J, 2008, 29(1): 96-103.
|
15. |
Nguyen J L, Yang W, Ito K, et al. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol, 2016, 1(3): 274-281.
|
16. |
Martin RM, Bachman MA. Colonization, infection, and the accessory genome of Klebsiella pneumoniae. Front Cell Infect Microbiol, 2018, 8: 4.
|
17. |
王欣, 沈丹丹, 刘银梅, 等. 重症监护病房患者检出耐碳青霉烯类肺炎克雷伯菌的危险因素分析. 中国呼吸与危重监护杂志, 2022, 21(3): 158-161.
|
18. |
Chen Y, Ying S, Jiang L, et al. A novel nomogram for predicting risk factors and outcomes in bloodstream infections caused by Klebsiella pneumoniae. Infect Drug Resist, 2022, 15: 1317-1328.
|
19. |
Van Loon K, Voor in 'T Holt AF, Vos MC. A systematic review and meta-analyses of the clinical epidemiology of carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother, 2017, 62(1): e01730-17.
|
20. |
Fortini A, Faraone A, Di Pietro M, et al. Antimicrobial stewardship in an Internal Medicine ward: effects on antibiotic consumption and on the use of carbapenems. Intern Emerg Med, 2018, 13(8): 1219-1226.
|
21. |
Lee Y R, Baker NT. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis, 2018, 37(8): 1411-1419.
|
22. |
Li Y, Shen H, Zhu C, et al. Carbapenem-resistant Klebsiella pneumoniae Infections among ICU admission patients in Central China: prevalence and prediction model. Biomed Res Int, 2019, 2019: 9767313.
|
23. |
Zhang P, Wang J, Hu H, et al. Clinical characteristics and risk factors for bloodstream infection due to carbapenem-resistant Klebsiella pneumoniae in patients with hematologic malignancies. Infect Drug Resist, 2020, 13: 3233-3242.
|
24. |
Giannella M, Trecarichi EM, De Rosa FG, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect, 2014, 20(12): 1357-1362.
|